Does Vaxart Inc (VXRT) offer a good opportunity for investors? | news.google.com • |
Vaxart (NASDAQ:VXRT) Shares Cross Above Two Hundred Day Moving Average of $0.85 | news.google.com • |
VXRT (Vaxart Inc) may reap gains as insiders became active recently | news.google.com • |
Checking in on Travere Therapeutics Inc (TVTX) after recent insiders movement | news.google.com • |
VTLE’s latest rating updates from top analysts. | news.google.com • |
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.1 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.03 | -0.09 | -0.12 | -400.00% |
2024-05-13 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2024-06-10 | FINNEY MICHAEL J | Director | 686.84K | Stock Award(Grant) |
2024-06-10 | HERON ELAINE J | Director | 40.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
-
-
$VXRT would be $15+ today. Mark it!!!
-
We will see $10 at open...and $12 by noon
-
-
All walls will be broken at open....insane volume
-
There are ZERO shares to short, and conference coming this evening. This can easily go upto $20 and if WSB are here, we can see a squeeze to $50!
-
This will run crazy today...watch $15 coming
-
$VXRT Opening tomorrow @15 IMHO.
-
Tomorrow would a nice short squeeze. We might see $12+
-
Tomorrow we will see huge gap up...$10 is nothing for such a promising pill, which has better results than Moderna and Pfizer. Buy/Hold and enjoy your gains
-
Just came in the India news :
Serum, Bharat Biotech got advance of Rs 2,500 crore for 16 crore doses, says government
Rupali Mukherjee / TNN / May 4, 2021, 02:18 IST
MUMBAI: The government on Monday said it had paid an advance of over Rs 2,500 crore to Serum Institute of India and Bharat Biotech for supply of 16 crore doses of Covid vaccine between May and July.
While Serum Institute is to supply 11 crore doses of Covishield, the rest will be Covaxin manufactured by Bharat Biotech. Based on the advance paid on April 28, the price works out to a little under Rs 160 per shot.
SII CEO Adar Poonawalla had suggested that the Centre should increase the price as the company needed to boost capacity.
The government’s statement came after Poonawalla’s interview to The Financial Times, where he had suggested the company did not expand capacity due to the absence of orders. Besides, the Centre has been facing criticism for not procuring enough vaccine before opening inoculations for those over 18 years.
It said that against an earlier order of 10 crore doses, Serum had delivered 8.7 crore shots till Monday, while Bharat Biotech had delivered 88 lakh against an order of 2 crore shots. The Centre had announced last month that it is making an advance payment of around Rs 3,000 crore to Serum Institute and Rs 1,500 crore to Bharat Biotech.
The controversy also forced Poonawalla to issue a statement, saying the firm has been working closely with the government for the past year and is committed to ramping up capacity. “...it is not possible to ramp up production overnight. We also need to understand that the population of India is huge and to produce enough doses for all adults is not an easy task. Even the most advanced countries and companies are struggling in relatively smaller populations,” he said, adding he would like to clarify since his (overall) comments may have been misinterpreted.
Poonawalla said against overall orders of over 26 crore doses, Rs 15 crore had been supplied to the government. “Another 11 crore doses will be supplied in the second channel for state and private hospitals,” he said. -
-
Added 5k @9.84...can’t wait to see this fly tomorrow PM to $11
-
I am holding my 3k shares tonight and putting sell limit at $25. I suggest don’t settle for pennies. This is a diamond stock, and will pay off BIG time!
-
We will see close above $11 and open tomorrow at $15
-
Tomorrow open at $15. Big investors will load tonight and tomorrow PM. Mark it
-
Wow. Diamond hands surely are not forged through easy gains.
“ A smooth sea never made a skilled sailor”
I read that on a fortune cookie once, hung it on my refrigerator, and throw it down whenever I feel the need to come off as a philosophical individual
Anyways, BULLISH
-
Wtf this some crazy ish lol I feel like Joe Briben has made the stock market a casino
-
What a result!! Better than Pfizer and Moderna!! This is going to rip hard...might see $20 soon
-
Does Vaxart Inc (VXRT) offer a good opportunity for investors?
news.google.com • -
VXRT (Vaxart Inc) may reap gains as insiders became active recently
news.google.com • -
VTLE’s latest rating updates from top analysts.
news.google.com • -
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics
news.google.com • -
Is Vaxart Inc (VXRT) a good investment opportunity?
news.google.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
seekingalpha.com • -
Vaxart Provides Business Update
globenewswire.com • -
Vaxart Announces $40 Million Underwritten Offering of Common Stock
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
globenewswire.com • -
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com •